

BUY

Last price	Rp 2,060
Target price	Rp 2,500
Upside potential	21.4 %

General Information

Ticker	KLBF
Sector	Healthcare
52-week range	1,520 - 2,080
Year-to-date return	27.6 %
Last price (18 Nov 2022)	2,060
Target price	2,500
Shares outstanding	46,255,641,410
Market cap.	95,286,621,304,600
Free float	19,051,122,725
Earnings per share (Usd) (Dec 2021)	67.92

Source: company, Profindo research

Shareholder structure

PT Ladang Ira Panen	10.46 %
PT Gira Sole Prima	10.29 %
PT Santa Seha Sanadi	10.06 %
PT Diplanala Bahana	9.50 %
PT Lucasta Murni Cemerlang	9.47 %
PT Bina Arta Charisma	8.25 %
Public (each below 5% ownership)	40.65 %
Sub-total	98.68 %
Treasury stock	1.32 %
Total	100.00 %

Source: company, Profindo research

Research analyst:

Setya Pambudi

setya.pambudi@profindo.com

Company Overview

PT Kalbe Farma Tbk (KLBF) merupakan perusahaan yang bergerak di bidang produk kesehatan. Perseroan memberikan solusi kesehatan terintegrasi melalui empat kelompok divisi usaha: divisi obat resep, divisi produk kesehatan, divisi nutrisi, dan divisi distribusi & logistik. Perseroan memasarkan produknya melalui lebih dari satu juta outlet yang menjangkau seluruh wilayah di Indonesia.

Saat ini, Perseroan merupakan perusahaan produk Kesehatan publik terbesar di Asia Tenggara. Dalam operasinya, Perseroan didukung oleh 41 perusahaan, baik anak usaha maupun entitas asosiasi.

Financial Performance

Perseroan mencatatkan penghasilan sebesar Rp 21.2 triliun pada kuartal III tahun 2022. Jumlah ini meningkat sebesar 10.9% dibanding periode yang sama tahun sebelumnya.

EBITDA Perseroan pada periode ini mengalami peningkatan sebesar 7.5% dibanding periode yang sama tahun sebelumnya. Pada periode ini, EBITDA Perseroan tercatat sebesar Rp 3.6 triliun dengan margin EBITDA sebesar 17.0%.

Perseroan mencatatkan laba bersih sebesar Rp 2.5 triliun dengan margin laba bersih sebesar 12.0% pada periode ini, dimana nilai laba bersih tersebut meningkat 9.0% dibanding periode yang sama tahun sebelumnya.

Valuation

Dengan metode valuasi relatif, Perseroan memperoleh rekomendasi BUY dengan target harga Rp 2,500. Rekomendasi ini didasarkan pada Price to Earnings growth (PEG), dengan 3 tahun earnings forecast Perseroan, sebesar 36.81x.

<i>(in mn. Idr.)</i>					
Simplified income statement	2019A	2020A	3Q21	2021A	3Q22
Net sales	\$ 22,633,476	\$ 23,112,655	\$ 19,098,695	\$ 26,261,195	\$ 21,181,771
Cost of goods sold	(12,390,009)	(12,866,332)	(10,819,414)	(14,977,410)	(12,447,213)
Gross profit	10,243,468	10,246,322	8,279,281	11,283,784	8,734,558
Selling expenses	(5,358,033)	(5,014,413)	(4,167,327)	(5,549,652)	(4,372,646)
General and administrative expenses	(1,288,558)	(1,391,608)	(1,051,912)	(1,421,999)	(1,048,326)
Research and development expenses	(286,655)	(285,055)	(220,442)	(290,761)	(223,261)
EBITDA	3,820,014	4,065,038	3,349,391	4,531,164	3,600,116
Depreciation expenses	(462,704)	(462,704)	(462,704)	(462,704)	(462,704)
EBITA	3,357,310	3,602,334	2,886,688	4,068,460	3,137,412
Amortization expenses	(47,088)	(47,088)	(47,088)	(47,088)	(47,088)
EBIT	3,310,223	3,555,246	2,839,600	4,021,372	3,090,324
Interest expenses and other income & expenses	92,394	72,386	136,051	121,893	146,121
EBT	3,402,617	3,627,633	2,975,651	4,143,265	3,236,446
Tax expenses	(865,015)	(828,010)	(651,340)	(911,257)	(702,230)
EAT	\$ 2,537,602	\$ 2,799,623	\$ 2,324,311	\$ 3,232,008	\$ 2,534,215

<i>(in %)</i>					
Profit Margin	2019A	2020A	3Q21	2021A	3Q22
Gross profit margin	45.3 %	44.3 %	43.3 %	43.0 %	41.2 %
EBITDA margin	16.9 %	17.6 %	17.5 %	17.3 %	17.0 %
EBIT margin	14.6 %	15.4 %	14.9 %	15.3 %	14.6 %
Net profit margin	11.2 %	12.1 %	12.2 %	12.3 %	12.0 %

<i>(in mn. Idr.)</i>					
Simplified balance sheet	2019A	2020A	3Q21	2021A	3Q22
Assets					
Current assets					
Cash and cash equivalents	\$ 3,040,487	\$ 5,207,929	\$ 5,647,004	\$ 6,216,248	\$ 4,143,904
Trade receivables					
Third parties - net	3,531,178	3,434,047	3,515,064	3,396,600	4,278,893
Related parties	41,677	43,174	28,139	34,418	40,427
Inventories - net	3,737,976	3,599,746	4,373,304	5,087,300	6,641,198
Other current assets components	871,173	790,436	859,643	977,644	1,045,008
Total current assets	11,222,491	13,075,332	14,423,154	15,712,210	16,149,431
Non-current assets					
Fixed assets - net	7,666,315	8,157,762	7,994,109	7,994,022	7,922,726
Other non-current assets components	1,375,921	1,331,206	1,849,513	1,960,403	2,114,997
Total non-current assets	9,042,236	9,488,968	9,843,622	9,954,426	10,037,723
Total assets	20,264,727	22,564,300	24,266,776	25,666,635	26,187,154
Liabilities					
Current liabilities					
Short-term bank loans	149,638	220,500	60,000	-	595,000
Trade payables					
Third parties	1,118,955	1,119,318	1,213,227	1,587,301	1,890,696
Related parties	96,906	121,068	198,088	80,295	76,465
Current maturities of:					
Bank loans	19,424	123,843	21,442	70,000	31,543
Lease liabilities	-	24,921	22,365	23,646	27,651
Finance lease payables	95	-	-	-	-
Other current liabilities components	1,192,091	1,566,576	1,809,974	1,773,415	1,631,905
Total current liabilities	2,577,109	3,176,226	3,325,097	3,534,656	4,253,260
Non-current liabilities					
Long-term debts - net of current maturities					
Bank loans	647,647	722,819	566,700	490,277	400,400
Lease liabilities	-	65,732	48,254	42,232	30,353
Finance lease payables	41	-	-	-	-
Other non-current liabilities components	334,347	323,440	334,985	333,592	354,321
Total non-current liabilities	982,036	1,111,992	949,939	866,101	785,074
Total liabilities	3,559,144	4,288,218	4,275,035	4,400,757	5,038,334
Equity					
Paid-in capital & additional paid-in capital	434,633	434,633	434,633	434,633	434,633
Retained earnings	15,361,121	16,875,671	17,850,963	18,746,849	19,601,043
Treasury stock	-	(2,063)	(2,063)	(2,063)	(1,003,973)
Other equity components	909,829	967,842	1,708,209	2,086,459	2,117,117
Total equity	16,705,582	18,276,082	19,991,741	21,265,878	21,148,820
Total liabilities and equity	\$ 20,264,727	\$ 22,564,300	\$ 24,266,776	\$ 25,666,635	\$ 26,187,154

<i>(in multiple)</i>					
Current & Debt to Equity Ratios	2019A	2020A	3Q21	2021A	3Q22
Current ratio	4.35 x	4.12 x	4.34 x	4.45 x	3.80 x
Debt to equity ratio	0.05 x	0.06 x	0.04 x	0.03 x	0.05 x

Profindo Research Team:**Setya Pambudi**

(Research Analyst)

setya.pambudi@profindo.com

ext 713

Indra Kelana

(Technical Analyst)

indra.kelana@profindo.com

ext 715

Profindo Equity Sales Team:**Jessie James**

(Head of Equity Sales)

jessie.james@profindo.com

ext 314

Gabriella Pratiwy

(Head of MarCom & OLT)

gabriella.pratiwy@profindo.com

ext 600

KANTOR PUSATPermata Kuningan Building, 19F
Jl. KuninganMulia, Kav. 9C, Guntur Setiabudi
South Jakarta 12980

Phone : +62 21 8378 0888

Fax : +62 21 8378 0909

WA : 0818 0772 5505

FB : ProklikProfindo

IG : @profindosekuritas

Telegram : RanGers Stock Community

Twitter : proclickRG

KANTOR PERWAKILAN**SERANG**IDX Indonesia Stock Exchange
Jl. Veteran No 39-40
Cimuncang, Kota Serang
Banten 42117**BANDUNG**IDX Indonesia Stock Exchange
Jl. PHH Mustofa No 33
Neglasari, Kec. Cibeunying Kaler,
Bandung 40124**DISCLAIMER**

This research report is prepared by PT PROFINDO SEKURITAS INDONESIA for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. The report has been prepared without regard to individual financial circumstance, need or objective of person to receive it. The securities discussed in this report may not be suitable for all investors. The appropriateness of any particular investment or strategy whether opined on or referred to in this report or otherwise will depend on an investor's individual circumstance and objective and should be independently evaluated and confirmed by such investor, and, if appropriate, with his professional advisers independently before adoption or implementation (either as is or varied).